Nicorandil | coronary artery disease, in hemodialysis patients | vs control | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
unstable angina | no data | PCI | no data | Coronary revascularization | no data | Hospitalization for angina | no data | Cardiovascular death or hospital admission for CHF | no data | CV death, MI hospitalization for HF | no data | cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | Coronary event | no data | cardiac death | no data | CABG | no data | Non fatal MI | no data | hospitalisation for heart failure | no data | All cause death | no data |
Trial | Studied treatment | Control | Patients |
---|
Nishimura, 2009 | nicorandil 15 mg daily | control | Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later |
| |
Nicorandil | | vs control | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
unstable angina | no data | PCI | no data | Coronary revascularization | no data | Hospitalization for angina | no data | Cardiovascular death or hospital admission for CHF | no data | CV death, MI hospitalization for HF | no data | cardiovascular events | no data | Cardiovascular death | no data | myocardial infarction (fatal and non fatal) | no data | stroke (fatal and non fatal) | no data | Coronary event | no data | cardiac death | no data | CABG | no data | Non fatal MI | no data | hospitalisation for heart failure | no data | All cause death | no data |
Trial | Studied treatment | Control | Patients |
---|
Nishimura, 2009 | nicorandil 15 mg daily | control | Maintenance hemodialysis patients who underwent percutaneous coronary artery intervention and had complete coronary revascularization (absence of both restenosis and de novo coronary lesion) at coronary arteriography 6 months later |
| |
Ranolazine | acute coronary syndrome, in all type of patients | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Recurrent ischemia | 0.87 [0.76 1.00] | p=1.00 | 0 | 6560 | 1 | MERLIN TIMI 36, | Cardiovascular death | 0.99 [0.79 1.26] | p=1.00 | 0 | 6560 | 1 | MERLIN TIMI 36, | myocardial infarction (fatal and non fatal) | 0.97 [0.81 1.17] | p=1.00 | 0 | 6560 | 1 | MERLIN TIMI 36, | All cause death | 0.98 [0.79 1.22] | p=1.00 | 0 | 6560 | 1 | MERLIN TIMI 36, |
Trial | Studied treatment | Control | Patients |
---|
MERLIN TIMI 36, 2007 | ranolazine 1000 mg twice daily for the duration of the trial (intitialy 200 mg intravenously for 1 hour, followed by an 80 mg/h intravenous infusion) | placebo | Hospitalized with NSTE-ACS; ischemic symptoms at rest within 48 hours; and at least one indicator of moderate to high risk, defined as elevated troponin or creatine kinase-myocardial band, ST-depression >0.1 mV, diabetes, or TIMI risk score for unstable angina/NSTEMI >=3 |
| |
Ranolazine | | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
MARIZA, 2004 | ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg) | placebo | Patients with angina-limited exercise | RAN080, 2005 | ranolazine IR 400mg TID | placebo | patients who had symptom-limited exercise |
| |
Ranolazine | | vs placebo (on top standard treatment) | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
CARISA 1000mg, 2004 | ranozaline 1000mg (in combination with beta-blockers or calcium antagonists) | placebo | patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem |
| |
Ranolazine | | vs placebo + amlodipine | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
ERICA, 2006 | ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d) | placebo + amlodipine (10 mg/d) | patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d) |
| |
Ranolazine | | vs placebo | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
MARIZA, 2004 | ranolazine 500 mg twice daily (sustained-release ranolazine 500, 1,000, or 1,500 mg) | placebo | Patients with angina-limited exercise | RAN080, 2005 | ranolazine IR 400mg TID | placebo | patients who had symptom-limited exercise |
| |
Ranolazine | | vs placebo (on top standard treatment) | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
CARISA 1000mg, 2004 | ranozaline 1000mg (in combination with beta-blockers or calcium antagonists) | placebo | patients with severe chronic angina who have symptoms of chronic angina and who experience angina and ischemia at low workloads despite taking standard doses of atenolol, amlodipine, or diltiazem |
| |
Ranolazine | | vs placebo + amlodipine | all NS | Endpoint | TE [95% CI] | p val | I2 | n | k | |
---|
Trial | Studied treatment | Control | Patients |
---|
ERICA, 2006 | ranolazine 1000 mg twice a day for 6 weeks + amlodipine (10 mg/d) | placebo + amlodipine (10 mg/d) | patients with stable chronic angina already treated with the maximal dose of amlodipine (10mg/d) |
| |